Abstract: The present invention relates to nutrition for dysphagia. More specifically it relates to a thickened composition for use in decreasing the laryngeal vestibule closure (LVC) time and/or decreasing the duration of swallowing response in a dysphagia patient, wherein the thickened composition comprises a thickening agent comprising galactomannan polysaccharide. The invention also pertains to a thickening agent for use in decreasing the laryngeal vestibule closure (LVC) time and/or decreasing the duration of swallowing response in a dysphagia patient who is consuming a composition to which the thickening agent comprising galactomannan polysaccharide has been added.

Abstract: The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.

Abstract: A method to predict the risk of eczema is provided based on differences in the development of microbiota and its metabolites in healthy infants and infants that develop eczema, and nutritional remedies based on this finding, in the form of lactate utilizing bacteria and fibres stimulating lactate utilizing bacteria.

Abstract: The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.

Abstract: The invention pertains to a process for simultaneous producing an infant formula product and an acidic dairy product from defatted animal milk, comprising (a) processing the milk into a casein stream, a whey protein stream and a lactose stream, by: (i) subjecting the defatted animal milk to a filtration step over a microfiltration membrane capable of retaining bacteria and permeating milk proteins, to provide a debacterialized milk as permeate; (ii) subjecting the permeate originating from step (i) to a filtration step over a microfiltration membrane capable of retaining casein and permeating whey proteins, to provide a casein stream as retentate and a permeate comprising whey protein; (iii) fractionating the permeate originating from step (ii) into a whey protein stream and a lactose stream; (b) combining part of the casein stream, at least part of the whey protein stream originating from step (a) and a lactose source to obtain a recombined stream, wherein the lactose source comprises acid whey; (c) using th

Abstract: The invention pertains to a process for simultaneous producing an infant formula product and a dairy product from defatted animal milk, comprising (a) processing the milk into a casein stream, a whey protein stream and a lactose stream by a combination of microfiltration and ultrafiltration, wherein the casein stream originates from the microfiltration as retentate, the whey protein stream originates from the ultrafiltration as retentate and the lactose stream originates from the ultrafiltration as permeate; (b) combining at least part of the whey protein stream originating from step (a) and a lactose source to obtain are combined stream; (c) using the recombined stream originating from step (b) in the manufacture of the infant formula product; and (d) using at least part of the casein stream originating from step (a) and defatted animal milk in the manufacture of the dairy product.

Abstract: The invention provides a method of analysing the consistency of stool, including the steps of: providing stool of an infant, capturing, with a portable device comprising a camera, an image of the stool, providing the captured image to an input layer of a pre-trained convolutional neural network, CNN, processing the captured image using the CNN to obtain, from a final layer of the CNN, a classification vector and to obtain information about a predicted score from the classification vector, wherein at least the final layer of the CNN has been customized so that each element of the classification vector corresponds to a score of a stool analysis scale, and storing information about the predicted store.

Abstract: The invention concerns composition comprising 2?-fucosyllactose for use in the treatment of virus induced diarrhea.

Abstract: The present invention concerns a process for manufacturing an infant formula product comprising: (a) subjecting an aqueous mixture having a protein component and a carbohydrate component to a heat treatment step; (b) mixing the aqueous mixture with a lipid component; (c) subjecting the aqueous mixture comprising the lipid component, the carbohydrate component and the heat-treated protein component to a homogenization and emulsification step to obtain a homogenized oil-in-water emulsion having a total solids content in the range of 45-73 wt %; (d) conveying the homogenized emulsion into an extruder, independently adding digestible carbohydrates and optionally dietary fibres to the extruder and extruding the contents of the extruder to obtain an extruded material; (e) preparing an infant formula product from the extruded material.

Abstract: Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

Abstract: The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

Abstract: A formula comprising a whey protein hydrolysate comprising specific beta-lactoglobulin derived peptides and probiotics for inducing oral immune tolerance against milk protein, preventing or treating of oral immune intolerance against milk protein, and/or reducing the risk of developing oral immune intolerance against milk protein.

Abstract: A formula comprising a whey protein hydrolysate comprising specific beta-lactoglobulin derived peptides and probiotics for inducing oral immune tolerance against milk protein, preventing or treating of oral immune intolerance against milk protein, and/or reducing the risk of developing oral immune intolerance against milk protein.

Abstract: A method to predict the risk of eczema is provided based on differences in the development of microbiota and its metabolites in healthy infants and infants that develop eczema, and nutritional remedies based on this finding, in the form of lactate utilizing bacteria and fibres stimulating lactate utilizing bacteria.

Abstract: A tube for a medical container has a tube wall which consists of at least two layers. According to the invention, at least one layer contains a styrene-containing thermoplastic polymer (S-TPE), in particular a styrene-butadiene block copolymer (SBC) or a copolyester, a copolyester ether or a cyclic olefin copolyester. The at least one other layer contains ethylene-vinyl acetate copolymer (EVA), preferably with a vinyl acetate (VA) portion in the ethylene-vinyl acetate copolymer of from 10% to 30%, preferably 14% to 28%. The EVA can be mixed with a thermoplastic polybutene and/or SEBS to improve the tube properties. The tube wall can have a two-layer structure with an inner or an outer layer which contains the S-TPE, copolyester, copolyester ether or cyclic olefin copolyester, or a three-layer structure with an outer and inner layer containing the S-TPE or copolyester or copolyester ether.

Abstract: The invention relates to a nutritional composition for infants, in particular infant formula, follow on formula or growing up milk. The invention further relates to the prevention of dry skin in an infant.

Abstract: Method for providing a container with food, the method comprising: providing a container for infant formula food, adding the food, sealing the container with a gas-tight membrane seal, adding an inner scannable code on the gas-tight membrane seal, closing the container with a tamper-proof closure means, so that the inner scannable code is not scannable without breaking a part of the tamper-proof closure means, and storing the inner scannable code in a database.

Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.

Abstract: The invention relates to nutritional compositions comprising specifically designed lipid globules that are especially suited for preterm infants, small for gestational age infants and infants with retarded growth due to physical or mental stress after birth, for promoting catch-up growth and/or for use in improving body composition, improving adipose tissue distribution, decreasing visceral adipose tissue based on body weight and/or on total adipose tissue, and/or decreasing the ratio visceral adipose tissue to subcutaneous adipose tissue, in such infants, and/or providing nutrition to such infants.